尹艷慧
 |
尹艷慧，女，北京大學醫學部免疫學系，副教授。1993年畢業於白求恩醫科大學英語醫學專業獲醫學學士學位，1996年於白求恩醫科大學免疫教研室獲碩士學位，2001年于吉林大學免疫教研室獲博士學位，2005年北京大學醫學部免疫學系博士後出站。1999至2001年日本德島大學訪問學者。擔任中國食品藥品監督管理局醫療器械評審專家；擔任INT J CAN, SCI REP，Cancer Biology & Medicine等雜誌審稿人。
目錄
研究方向
1.腫瘤的免疫細胞治療
2.腫瘤抗原在腫瘤微環境形成中的作用及其機制
獲獎情況
獲2008年度「北京大學醫學部優秀青年學者」稱號；作為主要參與人，完成的「新的腫瘤相關抗原的發現及其應用前景研究」，獲國家教育部自然科學獎一等獎，中華醫學科技獎二等獎，北京市科學技術獎二等獎；三項國內發明專利已獲授權；作為主要參與人申請的腫瘤-睾丸抗原NY-ESO-1抗原肽疫苗獲得中國FDA批准用於肝癌患者免疫治療的Ⅰ期臨床試驗。
學術成果
論文
1. Song X, Guo C, Zheng Y, Wang Y, Jin Z, Yin Y*. Post-transcriptional regulation of cancer/testis antigen MAGEC2 expression by TRIM28 in tumor cells. BMC Cancer. 2018, 18: 971-980.
2. Zeng P, Wang Y, Zheng Y, Song X, Yin Y*. Cancer-testis antigen HCA587/MAGEC2 interacts with the general transcription coactivator TAF9 in cancer cells. Mol Med Rep. 2018; 17: 3226-3231.
3. Song X, Hao J, Wang J, Guo C, Wang Y, He Q, Tang H, Qing X, Li Y, Zhang Y*, Yin Y*. The cancer/testis antigen MAGEC2 promotes amoeboid invasion of tumor cells by enhancing STAT3 signling. Oncogene. 2017; 36, 1476–1486.
4. Wang J#, Song X#, Guo C, Wang Y, Yin Y*. Establishment of MAGEC2-knockout cells and functional investigation of MAGEC2 in tumor cells.Cancer Sci. 2016; 107(12): 1888-1897.
5. Xiao Song#, Wenjie Song#, Ying Wang, Jingjing Wang, Yan Li, Xiaoping Qian, Xuewen Pang, Yu Zhang, Yanhui Yin*. MicroRNA-874 functions as a tumor suppressor by targeting cancer/testis antigen HCA587/MAGE-C2.J Cancer. 2016 ;7(6):656-663..
6. Hao J, Song X, Wang J, Guo C, Li Y, Li B, Zhang Y*, Yin Y*. Cancer-testis antigen MAGE-C2 binds Rbx1 and inhibits ubiquitin ligase-mediated turnover of cyclin E. Oncotarget. 2015, 6(19):42028-42039.
7. Li X, Peng J, Pang Y, Yu S, Yu X, Chen P, Wang W, Han , Zhang J,Yin Y*, Zhang Y*. Identification of a FOXP3(+)CD3(+)CD56(+) population with immunosuppressive function in cancer tissues of human hepatocellular carcinoma. Sci Rep. 2015, 5:14757.
8. Sun X, Jin Z, Song X, Wang J, Li Y, Qian X, Zhang Y, Yin Y*. Evaluation of KF23 variant 1 expression and relevance as a novel prognostic factor in patients with hepatocellular carcinoma. BMC Cancer. 2015, 15:961.
9. Jiaqing Hao, Rui Shen, Yan Li, Yu Zhang, Yanhui Yin*. Cancer-testis antigen HCA587/MAGE-C2 interacts with BS69 and promotes its degradation in the ubiquitin-proteasome pathway. Biochem Biophys Res Commun. 2014, 449(4): 386-391.
10. Lijie Zhang, Juanjuan Chen, Xiao Song, Weigang Wen, Yan Li, Yu Zhang, Yanhui Yin*. Cancer/Testis antigen HCA587-derived long peptide vaccine generates potent immunologic responses and antitumor effects in mouse model. Oncol Res. 2014,21(4):193-200.[1]